TICKERNERD
Menu
IONSIONSHealthcare · Biotechnology

IONS Stock Forecast: Ionis Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 3 Sept 2026
$58
−5.22% on the day

The 24 Wall Street analysts covering Ionis Pharmaceuticals, Inc. hold a median 12-month price target of $90 — +54.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 2 Sept 2026 — in the lower half.

Market cap
$10.0B
Ticker Nerd rank
48 / 100
Median analyst target
$90
Analysts covering
24
Revenue$267.9M−40.7% y/y
Operating income−$102.3M
Net income−$114.6M
Free cash flow$547.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.9%
1M
+6.7%
YTD
−26.5%
1Y
−3.9%
From 52W high
−32.8%
From 52W low
+12.3%
$52
$87
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IONS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ionis Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Sept 2026
48 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
90
Quality
79
Value
71
Revisions
69
Momentum
61
Accruals
38
Growth
29
Issuance
18
Size
16

Volatility (90): The share price has been relatively steady.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IONS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IONS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120Oct 25Jan 26Apr 26Jul 26IONSHigh $115Median $90Low $60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says24 analysts
19 Buy5 Hold0 Sell
Low $60Median $90High $115

The green dot is the last close — the median target sits +54.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 7 moved it down.

DateFirmActionRatingTarget
31 Aug 2026HC Wainwright & Co.ReiteratesBuy$115
19 Aug 2026BMO CapitalInitiatesMarket Perform$60
3 Aug 2026JP MorganMaintainsOverweight$72 → $76
3 Aug 2026JP MorganMaintainsOverweight—
30 July 2026HC Wainwright & Co.MaintainsBuy—
30 July 2026HC Wainwright & Co.MaintainsBuy$125 → $115
30 July 2026Wells FargoMaintainsOverweight—
30 July 2026Wells FargoMaintainsOverweight$100 → $95
21 July 2026GuggenheimMaintainsBuy$106 → $89
21 July 2026GuggenheimMaintainsBuy—
16 July 2026Wolfe ResearchDowngradePeer Perform—
16 July 2026Wolfe ResearchDowngradePeer Perform—
13 July 2026RBC CapitalMaintainsOutperform—
13 July 2026RBC CapitalMaintainsOutperform$100 → $85
10 July 2026BarclaysMaintainsOverweight—
10 July 2026BarclaysMaintainsOverweight$115 → $90
10 July 2026Canaccord GenuityMaintainsBuy$110 → $95
10 July 2026Canaccord GenuityMaintainsBuy—
10 July 2026CitigroupMaintainsBuy—
10 July 2026CitigroupMaintainsBuy$115 → $100

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IONS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IONS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 3 Sept 2026, Ionis Pharmaceuticals, Inc. returned −3.9% against +21.4% for the S&P 500, dividends included.

IONS vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130140150Oct 25Jan 26Apr 26Jul 26IONSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IONS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
2
Fundamentals

Ionis Pharmaceuticals, Inc. (IONS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−25.2×

Cheaper than 97% of US stocks

Price / sales
11.4×

Cheaper than 13% of US stocks

Price / book
22.6×

Cheaper than 4% of US stocks

EV / EBITDA
−17.5×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
−40.7%

Higher than 7% of US stocks

Earnings growth (YoY)
—
Gross margin
99.0%

Higher than 99% of US stocks

Operating margin
−38.2%

Higher than 19% of US stocks

Net margin
−64.7%

Higher than 8% of US stocks

Returns & dividend
Return on equity
−105.5%

Higher than 13% of US stocks

Return on assets
−12.4%

Higher than 25% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ionis Pharmaceuticals, Inc. (IONS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ionis Pharmaceuticals, Inc. has a market value of $10.0B and an enterprise value of $10.1B.

  • Revenue in the twelve months to 30 June 2026: $874.1M. The latest quarter shrank 40.7% year on year.

  • Net income over the same four quarters: −$565.2M, a −64.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.46.

  • Free cash flow in the twelve months to 30 June 2026: −$567.5M.

  • Shares outstanding: 165.9M.

  • Trailing P/E: −25.2×; forward P/E: −55.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Ionis Pharmaceuticals, Inc. employs 1,480 people — $591K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Sept 2026

Data provided by Twelve Data

Peers

IONS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IONSIonis Pharmaceuticals, Inc.$10.0B
48
PRAXPraxis Precision Medicines, Inc.$9.8B
44
KYMRKymera Therapeutics, Inc.$9.9B
73
CYTKCytokinetics, Inc.$10.0B
47
APGEApogee Therapeutics, Inc.$10.2B
35
PTGXProtagonist Therapeutics, Inc.$9.3B
97
TGTXTG Therapeutics, Inc.$9.0B
68

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ionis Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IONS news & analysis

ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients

Business Wire · 3 Sept 2026positive

Ionis announced that the FDA approved ZANVASTRO (zilganersen) as the first and only disease-modifying treatment for Alexander disease (AxD) in pediatric and adult patients. AxD is an ultra-rare, progressive, often fatal neurological disorder affecting motor, cognitive, autonomic, and gastrointestinal function.

Why it matters — This FDA approval gives Ionis its first and only disease-modifying treatment for Alexander disease, marking a significant regulatory milestone for the company's pipeline.

US FDA approves Ionis Pharma's therapy to treat rare brain disorder

Reuters · 3 Sept 2026positive

The U.S. FDA approved Ionis Pharmaceuticals' therapy for a rare genetic disorder affecting the brain's white matter, making it the first treatment approved for the condition.

Why it matters — This approval gives Ionis a first-of-its-kind commercial therapy for a rare brain disorder, potentially opening a new market for the company.

Ionis to present at upcoming investor conferences

Business Wire · 3 Sept 2026neutral

Ionis Pharmaceuticals announced that management will participate in fireside chats at the 21st Annual Wells Fargo Healthcare Conference on September 10, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026. Live webcasts of the presentations will be available on the company's website.

Why it matters — Investors and analysts tracking Ionis will have opportunities to hear directly from management at these two major investor conferences, which could provide updates on the company's pipeline and outlook.

Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone

The Motley Fool · 3 Sept 2026neutral

Ionis Pharmaceuticals experienced two clinical setbacks in its partnered programs in July, which triggered a steep sell-off. However, the financial impact of these setbacks was cushioned because they involved partnered programs rather than wholly owned ones.

Why it matters — An IONS watcher would care because the article suggests the sell-off was overdone given that the financial exposure from the clinical setbacks was limited by the partnered structure.

Why Is Ionis Pharmaceuticals (IONS) Up 17.2% Since Last Earnings Report?

Zacks Investment Research · 28 Aug 2026positive

Ionis Pharmaceuticals reported earnings 30 days ago, and its stock has risen 17.2% since that report. The article examines what may be next for the company's shares following the earnings release.

Why it matters — An IONS watcher would care because the article assesses the stock's performance and outlook following the recent quarterly earnings report.

FAQ

Frequently asked questions about IONS stock

What is the IONS stock price forecast for 2026-2027?

The 24 Wall Street analysts covering Ionis Pharmaceuticals, Inc. have a median 12-month price target of $90, with estimates ranging from $60 to $115. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IONS stock a buy right now?

Of the 24 analysts covering Ionis Pharmaceuticals, Inc., 19 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ionis Pharmaceuticals, Inc. 48 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IONS?

As at 2 Sept 2026, Ionis Pharmaceuticals, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (90 of 100).

Will IONS stock go up?

No one can know that. What the data says: the median 12-month target from 24 analysts implies +54.0% from the last close, and Ticker Nerd's factor model ranks Ionis Pharmaceuticals, Inc. 48 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IONS stock forecast for 2030?

No analyst covering Ionis Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IONS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $60 to $115 over the next 12 months.

How has IONS stock performed over the past year?

Ionis Pharmaceuticals, Inc. returned -3.9% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ionis Pharmaceuticals, Inc. do?

Ionis Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on discovering and developing RNA-targeted medicines.

What is the latest news on IONS?

The most recent item we track (Business Wire, 3 Sept 2026): "ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients". Ionis announced that the FDA approved ZANVASTRO (zilganersen) as the first and only disease-modifying treatment for Alexander disease (AxD) in pediatric and adult patients. AxD is an ultra-rare, progressive, often fatal neurological disorder affecting motor, cognitive, autonomic, and gastrointestinal function.

Company

About Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on discovering and developing RNA-targeted medicines. Using its proprietary antisense technology, Ionis creates therapies designed to modulate gene expression and address serious diseases, particularly in neurology and cardiometabolic care, as well as other high-need therapeutic areas. The company currently markets several medicines for conditions such as spinal muscular atrophy, hereditary amyloidosis, amyotrophic lateral sclerosis, and certain rare cardiovascular and metabolic disorders. Ionis also maintains an active pipeline of investigational programs and collaborates with pharmaceutical partners to expand the reach of its platform. Headquartered in Carlsbad, California, Ionis Pharmaceuticals plays a significant role in the biotechnology market as a leading developer of RNA-based therapeutics.

CEO Dr. Brett P. Monia Ph.D. · 1,480 employees · United States · https://www.ionis.com